Advanced

Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining

Mansour, Mohammed S.I.; Seidal, Tomas; Mager, Ulrich; Baigi, Amir LU ; Dobra, Katalin and Dejmek, Annika LU (2017) In Cancer Cytopathology 125(12). p.908-917
Abstract

BACKGROUND: Malignant mesothelioma (MM) is an aggressive, fatal tumor. Current therapeutic options only marginally improve survival. Programmed cell death ligand 1 (PD-L1) is a dominant mediator of immunosuppression, binding to programmed cell death 1 (PD-1). PD-L1 is up-regulated in cancer cells, and the PD-1/PD-L1 pathway plays a critical role in tumor immune evasion, thus providing a target for antitumor therapy. Further, a correlation between PD-L1 expression and prognosis has been reported. Studies performed on histological material have revealed expression of PD-L1 in MM, but no study has been performed on MM effusions thus far. METHODS: PD-L1 expression was determined by a commercially available antibody (clone 28-8) in 74... (More)

BACKGROUND: Malignant mesothelioma (MM) is an aggressive, fatal tumor. Current therapeutic options only marginally improve survival. Programmed cell death ligand 1 (PD-L1) is a dominant mediator of immunosuppression, binding to programmed cell death 1 (PD-1). PD-L1 is up-regulated in cancer cells, and the PD-1/PD-L1 pathway plays a critical role in tumor immune evasion, thus providing a target for antitumor therapy. Further, a correlation between PD-L1 expression and prognosis has been reported. Studies performed on histological material have revealed expression of PD-L1 in MM, but no study has been performed on MM effusions thus far. METHODS: PD-L1 expression was determined by a commercially available antibody (clone 28-8) in 74 formalin-fixed, paraffin-embedded cell blocks from body effusions obtained at diagnosis from patients with MM. The presence of MM cells was confirmed with CK5/6, calretinin, and EMA and the admixture of macrophages was assessed with CD68. Only cases containing more than 100 tumor cells were assessed. Membranous staining in tumor cells was considered positive. Survival time was calculated from the appearance of the first malignant effusion until death. RESULTS: Reactivity was observed in 23 of 61 (38%) of cases and was classified as ≥1%-5% (n = 9 cases), >5%-10% (n = 4 cases), >10%-50% (n = 4 cases), and >50% (n = 6 cases) positive cells. Survival times did not differ significantly between patients with PD-L1–positive and PD-L1–negative tumors. CONCLUSION: MM effusions are suitable for immune-cytochemical assessment of PD-L1 expression in malignant cells and the results are similar to those reported for histological specimens. Cancer Cytopathol 2017;125:908-17.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cytology, effusion, immunocytochemistry (ICC), malignant mesothelioma (MM), programmed cell death ligand 1 (PD-L1)
in
Cancer Cytopathology
volume
125
issue
12
pages
10 pages
publisher
Wiley-Blackwell
external identifiers
  • scopus:85038083776
  • wos:000418130100005
ISSN
1934-662X
DOI
10.1002/cncy.21917
language
English
LU publication?
yes
id
35dda173-e740-4423-8a70-252ca88f5341
date added to LUP
2018-01-12 08:27:58
date last changed
2018-01-16 13:29:50
@article{35dda173-e740-4423-8a70-252ca88f5341,
  abstract     = {<p>BACKGROUND: Malignant mesothelioma (MM) is an aggressive, fatal tumor. Current therapeutic options only marginally improve survival. Programmed cell death ligand 1 (PD-L1) is a dominant mediator of immunosuppression, binding to programmed cell death 1 (PD-1). PD-L1 is up-regulated in cancer cells, and the PD-1/PD-L1 pathway plays a critical role in tumor immune evasion, thus providing a target for antitumor therapy. Further, a correlation between PD-L1 expression and prognosis has been reported. Studies performed on histological material have revealed expression of PD-L1 in MM, but no study has been performed on MM effusions thus far. METHODS: PD-L1 expression was determined by a commercially available antibody (clone 28-8) in 74 formalin-fixed, paraffin-embedded cell blocks from body effusions obtained at diagnosis from patients with MM. The presence of MM cells was confirmed with CK5/6, calretinin, and EMA and the admixture of macrophages was assessed with CD68. Only cases containing more than 100 tumor cells were assessed. Membranous staining in tumor cells was considered positive. Survival time was calculated from the appearance of the first malignant effusion until death. RESULTS: Reactivity was observed in 23 of 61 (38%) of cases and was classified as ≥1%-5% (n = 9 cases), &gt;5%-10% (n = 4 cases), &gt;10%-50% (n = 4 cases), and &gt;50% (n = 6 cases) positive cells. Survival times did not differ significantly between patients with PD-L1–positive and PD-L1–negative tumors. CONCLUSION: MM effusions are suitable for immune-cytochemical assessment of PD-L1 expression in malignant cells and the results are similar to those reported for histological specimens. Cancer Cytopathol 2017;125:908-17.</p>},
  author       = {Mansour, Mohammed S.I. and Seidal, Tomas and Mager, Ulrich and Baigi, Amir and Dobra, Katalin and Dejmek, Annika},
  issn         = {1934-662X},
  keyword      = {cytology,effusion,immunocytochemistry (ICC),malignant mesothelioma (MM),programmed cell death ligand 1 (PD-L1)},
  language     = {eng},
  month        = {12},
  number       = {12},
  pages        = {908--917},
  publisher    = {Wiley-Blackwell},
  series       = {Cancer Cytopathology},
  title        = {Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining},
  url          = {http://dx.doi.org/10.1002/cncy.21917},
  volume       = {125},
  year         = {2017},
}